Ep. 376 - M&A momentum: 3Q public markets preview
From BioCentury This Week · · 33 min
This plays from the publisher's own server. We do not host a copy.
Description
M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview (https://www.biocentury.com/article/660013), asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust? Editor in Chief Simone Fishburn gives her perspective (https://www.biocentury.com/article/660055) on what incoming Prime Minister Andy Burnham’s agenda means for U.K. life sciences. The analysts also discuss Ionis’ ATTR-CM miss (https://www.biocentury.com/article/660068) and Takeda’s orexin program (https://www.biocentury.com/article/659997). This episode of the BioCentury This Week podcast has been brought to you by CBRE (https://www.cbre.com/).
View full story: https://www.biocentury.com/article/660118
#BiotechMA #BiotechInvesting #PublicMarkets #LifeSciences #DrugDevelopment
00:01 - Sponsor Message: CBRE 01:46 - 3Q Market Preview 10:54 - Burnham’s Britain 19:40 - Ionis' ATTR-CM Miss 29:12 - Takeda Orexin Program
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)